Publications
663 results found
Besse B, Felip E, Kim ES, et al., 2021, AcceleRET Lung: A Phase 3 Study of First-Line Pralsetinib in Patients with RET-Fusion plus Advanced/Metastatic NSCLC, Publisher: ELSEVIER SCIENCE INC, Pages: S44-S45, ISSN: 1556-0864
- Author Web Link
- Cite
- Citations: 5
Peters S, Scherpereel A, Cornelissen R, et al., 2021, First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743, Congress of the European-Society-for-Medical-Oncology (ESMO), Publisher: ELSEVIER, Pages: S1341-S1342, ISSN: 0923-7534
- Author Web Link
- Cite
- Citations: 8
Yang JYC-H, Schuler M, Popat S, et al., 2021, Afatinib for the treatment of NSCLC with uncommon EGFR mutations: An updated database of 1023 cases, Congress of the European-Society-for-Medical-Oncology (ESMO), Publisher: ELSEVIER, Pages: S965-S965, ISSN: 0923-7534
- Author Web Link
- Cite
- Citations: 3
Popat S, Jung HA, Lee SY, et al., 2021, Sequential afatinib (afa) and osimertinib (osi) in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) NSCLC who acquire the T790M resistance mutation: A non-interventional cohort study (UpSwinG), Congress of the European-Society-for-Medical-Oncology (ESMO), Publisher: ELSEVIER, Pages: S971-S972, ISSN: 0923-7534
- Author Web Link
- Cite
- Citations: 1
Dziadziuszko R, Ahn M-J, Kelly KA, et al., 2021, SKYSCRAPER-03: Phase III, open-label randomised study of atezolizumab plus tiragolumab vs durvalumab in patients with locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) who have not progressed after platinum-based concurrent chemoradiation (cCRT), Congress of the European-Society-for-Medical-Oncology (ESMO), Publisher: ELSEVIER, Pages: S947-S948, ISSN: 0923-7534
- Author Web Link
- Cite
- Citations: 3
Reinmuth N, Popat S, Paz-Ares L, et al., 2021, Health utility with tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC), Congress of the European-Society-for-Medical-Oncology (ESMO), Publisher: ELSEVIER, Pages: S985-S986, ISSN: 0923-7534
- Author Web Link
- Cite
- Citations: 2
Girard N, Ponce Aix S, Cedres S, et al., 2021, Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial, Congress of the European-Society-for-Medical-Oncology (ESMO), Publisher: ELSEVIER, Pages: S1342-S1342, ISSN: 0923-7534
- Author Web Link
- Cite
- Citations: 10
Miura S, Hsia T-C, Hung J-Y, et al., 2021, EGFR TKIs in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG), Congress of the European-Society-for-Medical-Oncology (ESMO), Publisher: ELSEVIER, Pages: S967-S968, ISSN: 0923-7534
Popat S, Kim HR, Ahn M-J, et al., 2021, Brigatinib (BRG) vs crizotinib (CRZ) in ALK TKI-naive ALK plus NSCLC: Final results from ALTA-1L, Congress of the European-Society-for-Medical-Oncology (ESMO), Publisher: ELSEVIER, Pages: S954-S955, ISSN: 0923-7534
Collins DC, Sundar R, Constantidinou A, et al., 2020, Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease, BMC Cancer, Vol: 20, ISSN: 1471-2407
Background: Malignant pleural mesothelioma (MPM) is traditionally characterized by local destructive spread of thepleura and surrounding tissues. Patient outcomes in MPM with distant metastatic dissemination are lacking.Methods: In this retrospective study, we reviewed a cohort of 164 MPM patients referred to a Phase I trials unit,aiming to describe identified metastatic sites, and correlate with clinical outcomes.Results: 67% of patients were diagnosed with distant metastatic disease with a high incidence of bone (19%),visceral (14%), contralateral lung (35%) and peritoneal metastases (22%). Peritoneal metastases were more likely inepithelioid versus biphasic/ sarcomatoid MPM (p = 0.015). Overall survival was 23.8 months with no statisticaldifference in survival between those with distant metastases and those without.Conclusions: This report highlights the frequency of distant metastases and encourages further radiologicalinvestigations in the presence of symptoms. In particular, given the relatively high incidence of bone metastases,bone imaging should be considered in advanced MPM clinical workflow and trial protocols. The presence of distantmetastases does not appear to have prognostic implications under existing treatment paradigms. This cohort ofMPM patients gives an indication of patterns of metastatic spread that are likely to become prevalent as prognosisimproves with emerging treatment paradigms.Keywords: Mesothelioma, Metastases, Pleural mesothelioma, Bone metastases
Cui W, Yousaf N, Bhosle J, et al., 2020, Real-world outcomes in thoracic cancer patients with severe Acute respiratory syndrome Coronavirus 2 (COVID-19): Single UK institution experience, Cancer Treatment and Research Communications, Vol: 25, Pages: 100261-100261, ISSN: 2468-2942
BACKGROUND: UK COVID-19 mortality rates are amongst the highest globally. Controversy exists on the vulnerability of thoracic cancer patients. We describe the characteristics and sequelae of patients with thoracic cancer treated at a UK cancer centre infected with COVID-19. METHODS: Patients undergoing care for thoracic cancer diagnosed with COVID-19 (RT-PCR/radiology/clinically) between March-June 2020 were included. Data were extracted from patient records. RESULTS: Thirty-two patients were included: 14 (43%) diagnosed by RT-PCR, 18 (57%) by radiology and/or convincing symptoms. 88% had advanced thoracic malignancies. Eleven of 14 (79%) patients diagnosed by RT-PCR and 12 of 18 (56%) patients diagnosed by radiology/clinically were hospitalised, of which four (29%) and 2 (11%) patients required high-dependency/intensive care respectively. Three (21%) patients diagnosed by RT-PCR and 2 (11%) patients diagnosed by radiology/clinically required non-invasive ventilation; none were intubated. Complications included pneumonia and sepsis (43% and 14% respectively in patients diagnosed by RT-PCR; 17% and 11% respectively in patients diagnosed by radiology/clinically). In patients receiving active cancer treatment, therapy was delayed/ceased in 10/12 (83%) and 7/11 (64%) patients diagnosed by RT-PCR and radiology/clinically respectively. Nine (28%) patients died; all were smokers. Median time from symptom onset to death was 7 days (range 3-37). CONCLUSIONS: The immediate morbidity from COVID-19 is high in thoracic cancer patients. Hospitalisation and treatment interruption rates were high. Improved risk-stratification models for UK cancer patients are urgently needed to guide safe cancer-care delivery without compromising efficacy.
Cui W, Cotter C, Sreter KB, et al., 2020, Case of Fatal Immune-Related Skin Toxicity From Sequential Use of Osimertinib After Pembrolizumab: Lessons for Drug Sequencing in Never-Smoking Non-Small-Cell Lung Cancer, JCO ONCOLOGY PRACTICE, Vol: 16, Pages: 842-+, ISSN: 2688-1527
- Author Web Link
- Cite
- Citations: 6
Scherpereel A, Antonia S, Bautista Y, et al., 2020, First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743, ESMO Immuno-Oncology Virtual Congress, Publisher: ELSEVIER, Pages: S1441-S1441, ISSN: 0923-7534
- Author Web Link
- Cite
- Citations: 9
Popat S, Curioni-Fontecedro A, Dafni U, et al., 2020, A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial, 44th Congress of the European-Society-for-Medical-Oncology (ESMO), Publisher: ELSEVIER, Pages: 1734-1745, ISSN: 0923-7534
- Author Web Link
- Cite
- Citations: 107
Zhang YZ, Brambilla C, Molyneaux PL, et al., 2020, Atypical mesothelial proliferation (amp) of the pleura: multidisciplinary approach, prognostic stratification and proposal of minimally invasive malignant pleural mesothelioma, Publisher: SPRINGER, Pages: S24-S25, ISSN: 0945-6317
Popat S, Navani N, Kerr KM, et al., 2020, Navigating diagnostic and treatment decisions in non-small cell lung cancer: expert commentary on the multidisciplinary team approach, The Oncologist, Vol: 26, Pages: E306-E315, ISSN: 1083-7159
Non‐small cell lung cancer (NSCLC) accounts for approximately one in five cancer‐related deaths, and management requires increasingly complex decision making by health care professionals. Many centers have therefore adopted a multidisciplinary approach to patient care, using the expertise of various specialists to provide the best evidence‐based, personalized treatment. However, increasingly complex disease staging, as well as expanded biomarker testing and multimodality management algorithms with novel therapeutics, have driven the need for multifaceted, collaborative decision making to optimally guide the overall treatment process. To keep up with the rapidly evolving treatment landscape, national‐level guidelines have been introduced to standardize patient pathways and ensure prompt diagnosis and treatment. Such strategies depend on efficient and effective communication between relevant multidisciplinary team members and have both improved adherence to treatment guidelines and extended patient survival. This article highlights the value of a multidisciplinary approach to diagnosis and staging, treatment decision making, and adverse event management in NSCLC.
Camidge DR, Kim HR, Ahn M-J, et al., 2020, Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer: second interim analysis of the Phase III ALTA-1L trial, Journal of Clinical Oncology, Vol: 38, Pages: 3592-3604, ISSN: 0732-183X
PURPOSEBrigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, demonstrated superior progression-free survival (PFS) and improved health-related quality of life (QoL) versus crizotinib in advanced ALK inhibitor–naive ALK-positive non–small cell lung cancer (NSCLC) at first interim analysis (99 events; median brigatinib follow-up, 11.0 months) in the open-label, phase III ALTA-1L trial (ClinicalTrials.gov identifier: NCT02737501). We report results of the second prespecified interim analysis (150 events).METHODSPatients with ALK inhibitor–naive advanced ALK-positive NSCLC were randomly assigned 1:1 to brigatinib 180 mg once daily (7-day lead-in at 90 mg once daily) or crizotinib 250 mg twice daily. The primary end point was PFS as assessed by blinded independent review committee (BIRC). Investigator-assessed efficacy, blood samples for pharmacokinetic assessments, and patient-reported outcomes were also collected.RESULTSTwo hundred seventy-five patients were randomly assigned (brigatinib, n = 137; crizotinib, n = 138). With median follow-up of 24.9 months for brigatinib (150 PFS events), brigatinib showed consistent superiority in BIRC-assessed PFS versus crizotinib (hazard ratio [HR], 0.49 [95% CI, 0.35 to 0.68]; log-rank P < .0001; median, 24.0 v 11.0 months). Investigator-assessed PFS HR was 0.43 (95% CI, 0.31 to 0.61; median, 29.4 v 9.2 months). No new safety concerns emerged. Brigatinib delayed median time to worsening of global health status/QoL scores compared with crizotinib (HR, 0.70 [95% CI, 0.49 to 1.00]; log-rank P = .049). Brigatinib daily area under the plasma concentration–time curve was not a predictor of PFS (HR, 1.005 [95% CI, 0.98 to 1.031]; P = .69).CONCLUSIONBrigatinib represents a once-daily ALK inhibitor with superior efficacy, tolerability, and QoL over crizotinib, making it a promising first-line treatment of ALK-positive NSCLC.
Yang JC-H, Schuler M, Popat S, et al., 2020, Afatinib in Asian and non-Asian patients (pts) with EGFR mutation positive (EGFRm plus ) NSCLC harboring major uncommon mutations, ESMO Asia Virtual Congress, Publisher: ELSEVIER, Pages: S1396-S1396, ISSN: 0923-7534
Miura S, Maerten A, Popat S, 2020, UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm plus ) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib, ESMO Asia Virtual Congress, Publisher: ELSEVIER, Pages: S1405-S1406, ISSN: 0923-7534
- Author Web Link
- Cite
- Citations: 1
Tokaca N, Cui W, Hazell S, et al., 2020, Squamous Non-Small-Cell Lung Cancer Molecularly Reclassified as Transdifferentiated Prostate Cancer Due to Identification of <i>TMPRSS2-ERG</i> Translocation With <i>SOX2</i> Amplification, JCO ONCOLOGY PRACTICE, Vol: 16, Pages: 695-+, ISSN: 2688-1527
Coleman N, Woolf D, Welsh L, et al., 2020, <i>EGFR</i> Exon 20 Insertion (A763_Y764insFQEA) Mutant NSCLC Is Not Identified by Roche Cobas Version 2 Tissue Testing but Has Durable Intracranial and Extracranial Response to Osimertinib, JOURNAL OF THORACIC ONCOLOGY, Vol: 15, Pages: E162-E165, ISSN: 1556-0864
- Author Web Link
- Cite
- Citations: 11
Griesinger F, Kim HR, Ahn M-J, et al., 2020, Brigatinib vs crizotinib in the phase 3 ALTA-1L trial: Updated results, Publisher: KARGER, Pages: 142-142, ISSN: 2296-5270
Bartlett EC, Kemp S, Ridge CA, et al., 2020, Baseline Results of the West London lung cancer screening pilot study - Impact of mobile scanners and dual risk model utilisation, LUNG CANCER, Vol: 148, Pages: 12-19, ISSN: 0169-5002
- Author Web Link
- Cite
- Citations: 25
Baas P, Scherpereel A, Nowak A, et al., 2020, First-Line Nivolumab plus Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743, Publisher: ELSEVIER SCIENCE INC, Pages: E42-E42, ISSN: 1556-0864
- Author Web Link
- Cite
- Citations: 34
Middleton G, Fletcher P, Popat S, et al., 2020, The National Lung Matrix Trial of personalized therapy in lung cancer (vol 49, pg 581, 2020), NATURE, Vol: 585, Pages: E21-E21, ISSN: 0028-0836
- Author Web Link
- Cite
- Citations: 1
Zhang YZ, Brambilla C, Molyneaux PL, et al., 2020, Presence of pleomorphic features but not growth patterns improves prognostic stratification of epithelioid malignant pleural mesothelioma by 2-tier nuclear grade, Histopathology, Vol: 77, Pages: 423-436, ISSN: 0309-0167
AIMS: Nuclear grade has been recently validated as a powerful prognostic tool in epithelioid malignant pleural mesothelioma (E-MPM). In other studies histological parameters including pleomorphic features and growth patterns were also shown to exert prognostic impact. The primary aims of our study are (1) externally validate the prognostic role of pleomorphic features in E-MPM and (2) investigate if evaluating growth pattern in addition to 2-tier nuclear grade improves prognostication. METHODS AND RESULTS: 614 consecutive cases of E-MPM from our institution over a period of 15 years were retrospectively reviewed, of which 51 showed pleomorphic features. E-MPM with pleomorphic features showed significantly worse overall survival compared those without (5.4 months vs 14.7 months). Tumours with predominantly micropapillary pattern showed the worst survival (6.2 months) followed by solid (10.5 months), microcystic (15.3 months), discohesive (16.1 months), trabecular (17.6 months) and tubulo-papillary (18.6 months). Sub-classification of growth patterns into high grade (solid, micropapillary) and low grade (all others) led to good separation of overall survival (10.5 months vs. 18.0 months) but did not predict survival independent of 2-tier nuclear grade. A composite score comprised of growth pattern and 2-tier nuclear grade did not improve prognostication compared with nuclear grade alone. Intra-tumoural heterogeneity in growth patterns is ubiquitous. CONCLUSIONS: Our findings support the incorporation of E-MPM with pleomorphic features in the epithelioid subtype as a highly aggressive variant distinct from 2-tier nuclear grade. E-MPM demonstrates extensive heterogeneity in growth pattern but its evaluation does not offer additional prognostic utility to 2-tier nuclear grade.
Lim E, Darlison L, Edwards J, et al., 2020, Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma., BMJ Open, Vol: 10, Pages: 1-9, ISSN: 2044-6055
INTRODUCTION: Mesothelioma remains a lethal cancer. To date, systemic therapy with pemetrexed and a platinum drug remains the only licensed standard of care. As the median survival for patients with mesothelioma is 12.1 months, surgery is an important consideration to improve survival and/or quality of life. Currently, only two surgical trials have been performed which found that neither extensive (extra-pleural pneumonectomy) or limited (partial pleurectomy) surgery improved survival (although there was some evidence of improved quality of life). Therefore, clinicians are now looking to evaluate pleurectomy decortication, the only radical treatment option left. METHODS AND ANALYSIS: The MARS 2 study is a UK multicentre open parallel group randomised controlled trial comparing the effectiveness and cost-effectiveness of surgery-(extended) pleurectomy decortication-versus no surgery for the treatment of pleural mesothelioma. The study will test the hypothesis that surgery and chemotherapy is superior to chemotherapy alone with respect to overall survival. Secondary outcomes include health-related quality of life, progression-free survival, measures of safety (adverse events) and resource use to 2 years. The QuinteT Recruitment Intervention is integrated into the trial to optimise recruitment. ETHICS AND DISSEMINATION: Research ethics approval was granted by London - Camberwell St. Giles Research Ethics Committee (reference 13/LO/1481) on 7 November 2013. We will submit the results for publication in a peer-reviewed journal. TRIAL REGISTRATION NUMBERS: ISRCTN-ISRCTN44351742 and ClinicalTrials.gov-NCT02040272.
Ahn M-J, Kim HR, Yang JC-H, et al., 2020, Brigatinib (BRG) vs crizotinib (CRZ) in Asian vs non-Asian patients (pts): Update from ALTA-1L, ANNALS OF ONCOLOGY, Vol: 31, Pages: S843-S844, ISSN: 0923-7534
- Author Web Link
- Cite
- Citations: 1
Cui W, Milner-Watts C, Faull I, et al., 2020, Circulating tumour (ct) DNA next generation sequencing (NGS) in advanced non-small cell lung cancer (mNSCLC): A UK single institution experience, ANNALS OF ONCOLOGY, Vol: 31, Pages: S867-S867, ISSN: 0923-7534
Yang JC-H, Schuler M, Popat S, et al., 2020, Afatinib in Asian and non-Asian patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC harboring uncommon mutations, ANNALS OF ONCOLOGY, Vol: 31, Pages: S860-S861, ISSN: 0923-7534
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.